Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.0
4.5
Journals
Cancers
Special Issues
The Theragnostics Era: New Radiopharmaceuticals for Diagnostics and Therapy
share announcement

The Theragnostics Era: New Radiopharmaceuticals for Diagnostics and Therapy

A special issue of Cancers (ISSN 2072-6694).

Deadline for manuscript submissions: closed (1 July 2023) | Viewed by 7071

Special Issue Editor

Dr. Salvatore Annunziata

E-Mail Website
Guest Editor
Unità di Medicina Nucleare, TracerGLab, Dipartimento Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico A. Gemelli IRCCS, 00168 Roma, Italy
Interests: nuclear medicine; radiopharmaceuticals; PET; radiomics

Special Issue Information

Dear Colleagues,

Therapy with radiopharmaceuticals is a field of great relevance in nuclear medicine in different clinical contexts, such as 131I for thyroid diseases and medullary neuroendocrine tumors, 90Y radioembolizazion in liver cancer, and 223Ra for bone metastases. In recent years, new specific ligands such as PSMA, Pentixafor, FAPI, and antibodies labeled with effective diagnostic radioisotopes (e.g., 68Ga, 18F, 64Cu) and therapeutic radioisotopes (e.g., 177Lu, 225Ac, 67Cu) have been developed and studied. The combined diagnostic and therapeutic power of these new radiopharmaceuticals has opened a new era of so-called theragnostics, exploiting a great scientific, clinical, and commercial interest.

We are pleased to invite you to contribute to this Special Issue called The Theragnostics Era: New Radiopharmaceuticals for Diagnostics and Therapy. This Special Issue aims to collect the most interesting papers on different theragnostic applications, including but not limited to oncology, endocrinology, gastroenterology, and immunology.

In this Special Issue, original research articles and reviews are welcome. Pre-clinical or clinical studies, experimental or observational studies, and senior or young investigators will be considered for publication.

We look forward to receiving your contributions.

Dr. Salvatore Annunziata
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • nuclear medicine
  • therapy
  • diagnostics
  • theranostics
  • theragnostics
  • PET
  • imaging
  • radiotherapy
  • radioligand
  • radiopharmaceuticals

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

Jump to: Other

23 pages, 1481 KiB  
Review
PSMA Radioligand Uptake as a Biomarker of Neoangiogenesis in Solid Tumours: Diagnostic or Theragnostic Factor?
by Alessio Rizzo, Sara Dall’Armellina, Daniele Antonio Pizzuto, Germano Perotti, Luca Zagaria, Valerio Lanni, Giorgio Treglia, Manuela Racca and Salvatore Annunziata
Cancers 2022, 14(16), 4039; https://doi.org/10.3390/cancers14164039 - 21 Aug 2022
Cited by 27 | Viewed by 3523
Abstract
Due to its overexpression on the surface of prostate cancer cells, prostate-specific membrane antigen (PSMA) is a relatively novel effective target for molecular imaging and radioligand therapy (RLT) in prostate cancer. Recent studies reported that PSMA is expressed in the neovasculature of various [...] Read more.
Due to its overexpression on the surface of prostate cancer cells, prostate-specific membrane antigen (PSMA) is a relatively novel effective target for molecular imaging and radioligand therapy (RLT) in prostate cancer. Recent studies reported that PSMA is expressed in the neovasculature of various types of cancer and regulates tumour cell invasion as well as tumour angiogenesis. Several authors explored the role of diagnostic and therapeutic PSMA radioligands in various malignancies. In this narrative review, we describe the current status of the literature on PSMA radioligands’ application in solid tumours other than prostate cancer to explore their potential role as diagnostic or therapeutic agents, with particular regard to the relevance of PSMA radioligand uptake as neoangiogenetic biomarker. Hence, a comprehensive review of the literature was performed to find relevant articles on the applications of PSMA radioligands in non-prostate solid tumours. Data on the general, methodological and clinical aspects of all included studies were collected. Forty full-text papers were selected for final review, 8 of which explored PSMA radioligand PET/CT performances in gliomas, 3 in salivary gland malignancies, 6 in thyroid cancer, 2 in breast cancer, 16 in renal cell carcinoma and 5 in hepatocellular carcinoma. In the included studies, PSMA radioligand PET showed promising performance in patients with non-prostate solid tumours. Further studies are needed to better define its potential role in oncological patients management, especially in those undergoing antineoangiogenic therapies, and to assess the efficacy of PSMA-RLT in this clinical context. Full article
(This article belongs to the Special Issue The Theragnostics Era: New Radiopharmaceuticals for Diagnostics and Therapy)
►▼ Show Figures

Figure 1

Other

Jump to: Review

13 pages, 853 KiB  
Systematic Review
Clinical Applications of Immuno-PET in Lymphoma: A Systematic Review
by Elizabeth Katherine Anna Triumbari, David Morland, Riccardo Laudicella, Matteo Bauckneht, Domenico Albano and Salvatore Annunziata
Cancers 2022, 14(14), 3488; https://doi.org/10.3390/cancers14143488 - 18 Jul 2022
Cited by 6 | Viewed by 2700
Abstract
Objective: Immuno-positron emission tomography (iPET) combines the sensitivity of the PET imaging technique and the targeting specificity of radio-labelled monoclonal antibodies (mAb). Its first clinical applications in humans were described in the late 1990s, and several pathologies have benefitted from this molecular imaging [...] Read more.
Objective: Immuno-positron emission tomography (iPET) combines the sensitivity of the PET imaging technique and the targeting specificity of radio-labelled monoclonal antibodies (mAb). Its first clinical applications in humans were described in the late 1990s, and several pathologies have benefitted from this molecular imaging modality since then. Our scope was to assess current clinical applications of immuno-PET in patients with lymphoma. Therefore, a systematic review of the published literature was performed. Methods: PubMed/Medline and Scopus databases were independently searched by two nuclear medicine physicians, to identify studies describing the clinical use of immuno-PET in patients with lymphoma. Methodological quality of the included articles was assessed by using the Quality Assessment of Diagnostic Accuracy Studies criteria. The studies were then analyzed concerning the molecular target of interest. Results: The initial search yielded 1407 articles. After elimination of duplicates, 1339 titles/abstracts were evaluated. Only two articles were found to comply with the inclusion criteria and two more were found during the cross-reference check. Among the four included articles, three described the use of 89Zr-labelled antibodies targeting CD20+ relapsed/refractory B-cell lymphomas and one concerned the use of 68Ga-labelled mAb targeting CXCR4 in patients with non-Hodgkin lymphomas. Conclusions: Very limited literature data are currently available on the clinical use of iPET in patients with lymphoma. This technique is encountering obstacles in its wider use, possibly because of the need of specific facilities, unfavorable dosimetry, and unclear correlation of immuno-tracer biodistribution with patients’ clinical and tumors’ molecular characteristics. However, iPET may represent a useful tool to non-invasively visualize the heterogenous individual immunological environment, thus potentially guiding treatment-planning in lymphoma patients, and hence deserves further exploitation. Full article
(This article belongs to the Special Issue The Theragnostics Era: New Radiopharmaceuticals for Diagnostics and Therapy)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop